We are alleviating the toxicity of the anticancer drug CPT-11 by modulating components of the GI microbiome. CPT-11 is essential in treating colorectal and pancreatic cancer, but dose-limiting toxicity severely reduces its efficacy. This toxicity is caused by a bacterial enzyme in enteric microbial symbiotes. The enzyme, beta glucuronidase, removes the inactivating glucuronic acid sugar from CPT-11's key metabolite, which reactivates the drug in the GI and produces epithelial cell death and acute diarrhea. We hypothesized that the selective, non-lethal inhibition of microbial beta glucuronidases would alleviate this side effect. This hypothesis tested true in proof-of-concept molecular-to-animal studies conducted in the previous project period. We will now advance the project in three crucial ways. First, we will characterize the range of active ?-glucuronidases present in the GI microbiome using structural biology and biochemistry. Second, we will create differentially optimized bacterial beta glucuronidase inhibitors via structural and chemical biology. Third, using deep-sequencing and metagenomics, we will unravel how this approach impacts the composition and activity of the GI microbiome. In summary, we seek to advance a novel paradigm - inhibiting specific microbial enzymes for therapeutic gain without harming the bacterial symbiotes essential for human health.
We are alleviating the toxicity of the anticancer drug CPT-11 by modulating components of the GI microbiome. The results will reveal fundamental aspects of mammalian-microbial symbiosis and improve cancer chemotherapy.
|Pellock, Samuel J; Walton, William G; Biernat, Kristen A et al. (2018) Three structurally and functionally distinct ?-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem 293:18559-18573|
|Bhatt, Aadra P; Gunasekara, Dulan B; Speer, Jennifer et al. (2018) Nonsteroidal Anti-Inflammatory Drug-Induced Leaky Gut Modeled Using Polarized Monolayers of Primary Human Intestinal Epithelial Cells. ACS Infect Dis 4:46-52|
|Pellock, Samuel J; Creekmore, Benjamin C; Walton, William G et al. (2018) Gut Microbial ?-Glucuronidase Inhibition via Catalytic Cycle Interception. ACS Cent Sci 4:868-879|
|Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248|
|Bhatt, Aadra P; Redinbo, Matthew R; Bultman, Scott J (2017) The role of the microbiome in cancer development and therapy. CA Cancer J Clin 67:326-344|
|Pollet, Rebecca M; D'Agostino, Emma H; Walton, William G et al. (2017) An Atlas of ?-Glucuronidases in the Human Intestinal Microbiome. Structure 25:967-977.e5|
|Pellock, Samuel J; Redinbo, Matthew R (2017) Glucuronides in the gut: Sugar-driven symbioses between microbe and host. J Biol Chem 292:8569-8576|
|Redinbo, Matthew R (2017) Microbial Molecules from the Multitudes within Us. Cell Metab 25:230-232|
|Ghodge, Swapnil V; Biernat, Kristen A; Bassett, Sarah Jane et al. (2016) Post-translational Claisen Condensation and Decarboxylation en Route to the Bicyclic Core of Pantocin A. J Am Chem Soc 138:5487-90|
|Wierdl, Monika; Tsurkan, Lyudmila; Hatfield, M Jason et al. (2016) Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer. Br J Pharmacol 173:2811-8|
Showing the most recent 10 out of 48 publications